<DOC>
	<DOCNO>NCT02137746</DOCNO>
	<brief_summary>The purpose study assess safety second cycle DCVAC/PCa patient complete first cycle DCVAC/PCa clinical trial SP003 without objective progression disease .</brief_summary>
	<brief_title>Study Allow Second Treatment Cycle DCVAC Patients With Localized Prostate Cancer</brief_title>
	<detailed_description>Same brief summary</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male 18 year old Histologically confirm prostate adenocarcinoma Stage pathological tumor2 ( pT2 ) Post radical Primary Prostatectomy Completion DCVAC/PCa arm Study SP003 , without objective progression disease Prior androgen deprivation therapy prostate cancer Peripheral neuropathy Common Toxicity Criteria ( CTC ) grade 2 great Other uncontrolled intercurrent illness Treatment immunotherapy PCa Clinically significant cardiovascular disease Active autoimmune disease require treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Radical Prostatectomy</keyword>
</DOC>